First copies of Gilead’s SBECD-enabled remdesivir to start selling in Bangladesh
According to Hindustan Times, Bangladesh’s Beximco Pharmaceuticals Ltd. has become the world’s first company to start selling the generic version
Author: Tamas Sohajda
Cyclolab R&D Director
Voluntary Licensing Agreements for Remdesivir
Gilead has signed non-exclusive voluntary licensing agreements with five generic pharmaceutical manufacturers based in India and Pakistan to further expand
Gilead Announces Approval of Veklury® (remdesivir) in Japan for Patients With Severe COVID-19
Japan approved the Gilead Sciences antiviral drug remdesivir Thursday for treatment of severe COVID-19 patients, under an exceptional approval pathway
UC Berkeley, Excivion and CycloLab develop antiviral cyclodextrins against SARS-CoV-2
UC Berkeley, Excivion and Cyclolab announce a supplemental grant awarded to UC Berkeley by the National Institutes of Health to evaluate a wide
Gilead outlines plans to distribute COVID-19 drug worldwide
Gilead on Tuesday said it is negotiating with overseas drug manufacturers to license its SBECD-enabled coronavirus treatment remdesivir in an effort
Az amerikai gyógyszerhatóság (FDA) engedélyezte a ciklodextrinnel formulázott remdesivir használatát COVID-19 kezelésére
A Gilead Sciences, Inc. amerikai gyógyszercég tegnap bejelentette, hogy a U.S. Food and Drug Administration (FDA, amerikai gyógyszerhatóság) úgynevezett “emergency
SBECD-enabled Remdesivir Receives FDA’s Emergency Use Authorization for the Treatment of COVID-19
Gilead Sciences, Inc. yesterday announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for
Gilead’s Remdesivir meets main goal of trial in COVID-19 patients
Gilead Sciences today announced that preliminary results of a coronavirus drug trial showed at least 50% of patients treated with
Japan to approve remdesivir for coronavirus patients in May
Prime Minister Shinzo Abe said Monday that Japan will soon approve the SBECD-eanbled anti-viral drug remdesivir for the treatment of
Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment
A Chicago hospital treating severe Covid-19 patients with Gilead Sciences’ antiviral medicine SBECD-enabled remdesivir in a closely watched clinical trial is